Ecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006, 24(33):5201?206. 44. Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP: Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011, 29(7):868?74. 45. El-Rayes BF, Zalupski M, Bekai-Saab T, Heilbrun LK, Hammad N, Patel B, Urba S, Shields AF, Vaishampayan U, Dawson S, et al: A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol 2010, 21(10):1999?004. 46. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, et al: Bevacizumab in mixture with chemotherapy as first-line therapy in sophisticated gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011, 29(30):3968?976. 47. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O’Bryant C, Chow LQ, Serkova NJ, et al: Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a totally human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial development aspect receptor-2. J Clin Oncol 2010, 28(5):780?87. 48. Fuchs CS, Tomasek J, Cho JY, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, et al: REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the therapy of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following illness progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy [abstract]. J Clin Oncol 2012(suppl 34):LBA5. http://asco.org/. 49. Tian S, Quan H, Xie C, Guo H, L?F, Xu Y, Li J, Lou L: YN968D1 is often a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.Formula of (5-Bromopyrazin-2-yl)methanol Cancer Sci 2011, 102(7):1374?380.Fmoc-5-Chloro-L-tryptophan Chemical name Qiu and Xu Biomarker Investigation 2013, 1:32 http://biomarkerres.PMID:33516645 org/content/1/1/Page eight of50. Li J, Qin S, Xu J, Guo WJ, Xiong JP, Bai Y, Sun G, Yang Y, Wang L, Xu N, et al: A randomized, double-blind, multicenter, phase, three-arm, placebo-control study of apatinib as third-line therapy in sufferers with metastatic gastric carcinoma [abstract]. J Clin Oncol 2011, 29(Suppl):4019. 51. Sharma T, Dhingra R, Singh S, Sharma S, Tomar P, Malhotra M, Bhardwaj TR: Aflibercept: a novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the therapy of several tumors. Mini Rev Med Chem 2013, 13(four):530?40. 52. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, et al: VEGFTrap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002, 99(17):11393?1398. 53. Konner J, Dupont J: Use of soluble recombinant decoy VEGF trap to inhibit VEGF activity. Clin Colorectal Cancer 2004, 4:S81 85. 54. Lassoued W, Murphy D, Tsai J, Oueslati R, Thurston G, Lee WM: Impact of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors. Cancer Biol Ther 2011, ten(12):1326?333. 55. Maulik G, Shrikhande A, Kijima T, Ma Computer, Morrison PT, Salgia R: Part on the hepatocyte growth element receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Development Issue Rev 2002, 13(1):41. 56. Galland F, Stef.